Lion's Jaw

Lion's Jaw, known medically as craniomandibular osteopathy (CMO), is a non-neoplastic, proliferative bone disease that affects the mandible and other bones of the skull in growing dogs. The condition is characterized by irregular, excessive new bone formation that replaces normal bone tissue, leading to bilateral swelling of the jaw that gives the affected dog's face a broad, lion-like appearance. This distinctive visual presentation is the origin of the condition's common name.

The disease was first described in veterinary literature in the 1950s, primarily in Scottish terrier breeds. Since then, it has been identified across a wider range of breeds, though it remains most prevalent among terrier lines. CMO is a self-limiting condition, meaning it typically ceases to progress once the dog reaches skeletal maturity, usually between 11 and 13 months of age. However, the period of active bone proliferation can be intensely painful and debilitating for the affected puppy.

The underlying mechanism involves cyclical episodes of bone resorption and irregular new bone deposition along the periosteum of the mandible, tympanic bullae, and occasionally the long bones. Unlike cancerous bone growth, CMO does not metastasize or invade surrounding soft tissues. The abnormal bone that forms is structurally disorganized, consisting of woven bone rather than the organized lamellar bone found in healthy skeletal tissue.

While CMO is not life-threatening in most cases, severe presentations can significantly impair a dog's ability to open its mouth, eat, and drink. In rare instances, the proliferative bone growth can be so extensive that it fuses the temporomandibular joint, permanently restricting jaw mobility. Early recognition and appropriate supportive care are essential for managing pain and maintaining adequate nutrition during the active phase of the disease.

Craniomandibular osteopathy is primarily a hereditary condition with a well-documented genetic basis in certain breeds. In West Highland White Terriers, the disease follows an autosomal recessive inheritance pattern, meaning a puppy must inherit the defective gene from both parents to develop the condition. Dogs that carry only one copy of the gene are asymptomatic carriers, making it possible for apparently healthy parents to produce affected offspring. The specific gene responsible has been mapped to canine chromosome 5 in some terrier breeds.

Beyond genetics, the exact triggers that initiate the abnormal bone growth remain under investigation. Some researchers have proposed that the condition may involve a dysregulation of bone metabolism during the rapid growth phase of puppyhood. The cyclical nature of the disease, with episodes of active bone proliferation alternating with periods of relative quiescence, suggests involvement of signaling pathways that regulate osteoblast and osteoclast activity during skeletal development.

Environmental factors do not appear to play a significant role in the development of CMO, though nutritional status and overall health may influence the severity of symptoms. There is no evidence linking the condition to infectious agents, trauma, or dietary imbalances. The disease occurs with equal frequency in male and female dogs, indicating no sex-linked component to its inheritance.

Breed predisposition is the strongest identified risk factor. Terrier breeds, particularly West Highland White Terriers, Scottish Terriers, and Cairn Terriers, carry the highest risk. However, CMO has also been documented in larger breeds including Labrador Retrievers, Great Danes, Doberman Pinschers, English Bulldogs, and Boxers. In non-terrier breeds, the inheritance pattern may differ, and the condition can present with involvement of bones beyond the mandible, including the long bones of the limbs.

The onset of craniomandibular osteopathy typically occurs between 3 and 8 months of age, coinciding with the period of most active skeletal growth. The earliest and most consistent sign is intermittent pain when the puppy attempts to open its mouth or chew. Owners may first notice that their puppy is reluctant to eat or play with toys, dropping food from its mouth, or crying out when yawning or being touched around the head and jaw. These episodes of pain tend to be cyclical, with flare-ups lasting days to weeks followed by periods of apparent improvement.

As the condition progresses, bilateral swelling along the lower jaw becomes increasingly apparent. The mandible takes on a thickened, bony feel that is distinctly different from soft tissue swelling caused by infection or trauma. In some cases, the swelling extends to the base of the skull behind the ears, corresponding to proliferative changes in the tympanic bullae. The degree of swelling can vary considerably between individuals, ranging from subtle thickening detectable only on palpation to dramatic enlargement that visibly alters the dog's facial profile.

Systemic signs often accompany the episodes of active bone proliferation. Affected puppies may develop intermittent fevers, sometimes reaching 104 to 106 degrees Fahrenheit, which can be mistaken for signs of infection. Lethargy, decreased appetite, and weight loss are common during flare-ups. Some puppies become reluctant to be touched on the head or face and may show signs of irritability or behavioral changes due to chronic pain. Excessive drooling may occur when jaw swelling restricts normal swallowing.

In severe cases, the abnormal bone growth can physically restrict the range of motion of the temporomandibular joint, limiting how far the dog can open its mouth. This restriction can progress to the point where the puppy is unable to eat solid food and struggles even with soft or liquid diets. Muscle atrophy of the temporal and masseter muscles may develop secondary to disuse, further contributing to the altered facial appearance. Lymph node enlargement in the submandibular region can also occur as a secondary inflammatory response.

Diagnosis of craniomandibular osteopathy is based on a combination of clinical presentation, patient signalment, and diagnostic imaging. A veterinarian presented with a young terrier-breed puppy showing jaw pain, bilateral mandibular swelling, and intermittent fever will typically have CMO high on their differential diagnosis list. However, several other conditions can mimic aspects of CMO, making definitive diagnostic confirmation important for appropriate treatment planning.

Radiographic imaging is the primary diagnostic tool for confirming CMO. Skull radiographs reveal characteristic bilateral, irregular proliferative bone formation along the mandible and often the tympanic bullae. The new bone appears as dense, irregular periosteal proliferation with a rough, lumpy contour that contrasts sharply with the smooth cortical surface of normal bone. In early stages, the radiographic changes may be subtle, consisting of mild periosteal reaction along the ventral mandible. More advanced cases show extensive irregular bone deposition that can obscure normal anatomical landmarks.

Advanced imaging modalities such as computed tomography (CT) provide superior detail for evaluating the extent of bone involvement, particularly when assessing the temporomandibular joint and tympanic bullae. CT imaging can detect early changes that may not be visible on standard radiographs and offers three-dimensional reconstruction capabilities that help the veterinarian visualize the spatial relationship between the abnormal bone and critical structures. This information can be valuable for prognostic assessment and surgical planning in severe cases.

Differential diagnoses that must be considered include osteomyelitis of the mandible (bacterial bone infection), neoplastic conditions such as osteosarcoma or multilobular osteochondrosarcoma, hypertrophic osteodystrophy, and temporomandibular joint disorders. Blood work typically reveals non-specific findings during active episodes, including elevated inflammatory markers such as C-reactive protein and mild elevation of alkaline phosphatase consistent with active bone remodeling. Bone biopsy is rarely necessary for diagnosis but, when performed, reveals characteristic findings of irregular woven bone formation with prominent osteoblastic activity and no evidence of neoplastic cells.

Genetic testing is available for some terrier breeds and can identify carriers of the autosomal recessive gene associated with CMO. While genetic testing does not replace clinical diagnosis, it serves an important role in breeding programs aimed at reducing the incidence of the condition in predisposed breeds.

There is no cure for craniomandibular osteopathy, and treatment is focused on managing pain, maintaining nutrition, and supporting the puppy through the active phase of the disease until skeletal maturity is reached. The cornerstone of treatment is anti-inflammatory and analgesic therapy. Non-steroidal anti-inflammatory drugs (NSAIDs) formulated for veterinary use, such as meloxicam or carprofen, are typically the first-line medications prescribed to reduce inflammation and control pain during flare-ups.

In cases where NSAIDs alone are insufficient to manage pain, corticosteroids such as prednisone may be prescribed for short courses during acute episodes. Corticosteroids are potent anti-inflammatory agents that can significantly reduce pain and swelling, but their long-term use in growing puppies carries risks including immunosuppression, gastrointestinal side effects, and potential interference with normal skeletal development. For this reason, corticosteroid use is typically reserved for more severe presentations and is tapered as quickly as clinical improvement allows.

Nutritional management is a critical component of treatment, particularly for puppies whose jaw mobility is significantly restricted. Softened or blenderized food, gruel-like consistency diets, and calorie-dense formulations help ensure adequate nutritional intake when chewing is painful or mechanically restricted. In rare severe cases where the puppy is unable to consume sufficient calories orally, placement of a feeding tube may be necessary as a temporary measure. Maintaining appropriate caloric and nutritional intake is essential for supporting the continued growth and development of the young dog.

Additional pain management strategies may include gabapentin for neuropathic pain control, tramadol for supplemental analgesia, and cold compresses applied externally to the swollen areas during acute flare-ups. Environmental modifications such as elevated food and water bowls, minimizing the need for the puppy to lower its head, and avoiding toys that require vigorous chewing can help reduce pain triggers. Regular veterinary monitoring throughout the active phase of the disease allows for adjustment of the treatment plan as symptoms wax and wane.

Physical therapy exercises to maintain jaw range of motion may be recommended in cases where temporomandibular joint restriction is developing. These exercises must be performed gently and only under veterinary guidance to avoid exacerbating pain or causing additional damage to the inflamed tissues.

The prognosis for dogs with craniomandibular osteopathy is generally favorable, as the condition is self-limiting and typically resolves once the dog reaches skeletal maturity between 11 and 13 months of age. In most cases, the abnormal bone that formed during the active phase gradually remodels over time, and the mandible and skull return to a more normal appearance and function. Many dogs that experienced mild to moderate CMO go on to live completely normal lives with no lasting functional impairment.

The degree of recovery is directly related to the severity of bone proliferation during the active phase and whether the temporomandibular joint was significantly affected. Dogs with mild to moderate involvement typically experience complete resolution of symptoms and full return of normal jaw function. The remodeling process may take several months beyond the cessation of active disease, and some residual bony thickening may persist on palpation even after clinical signs have fully resolved.

In more severe cases, particularly those where extensive bone proliferation involved the temporomandibular joint, permanent restriction of jaw opening may result. These dogs may retain a limited range of jaw motion that requires ongoing dietary modification, such as feeding softened food cut into small pieces that the dog can manage within its reduced gape. Severe temporomandibular joint ankylosis, while uncommon, represents the most serious potential long-term complication and may require surgical intervention to restore functional jaw mobility.

A small percentage of dogs with very severe CMO may be euthanized during the active phase due to intractable pain, inability to maintain adequate nutrition, or severely compromised quality of life despite aggressive supportive care. This outcome is rare with modern pain management protocols but remains a possibility in the most extreme presentations. Owners should be counseled that while the active disease phase can be challenging, the majority of affected dogs improve significantly once skeletal maturity is reached.

Dogs that recover from CMO do not experience recurrence of the condition in adulthood. There is no increased risk of other bone diseases or neoplastic conditions as a result of having had CMO. Recovered dogs can participate in normal activities, including regular exercise and play, once the active phase has resolved and any residual discomfort has subsided.

The terrier breeds most commonly affected by craniomandibular osteopathy share a close genetic lineage, which explains the concentration of the disease within this breed group. West Highland White Terriers have the highest documented prevalence, and extensive breeding studies in this breed have confirmed the autosomal recessive inheritance pattern. Responsible breeders of Westies increasingly utilize genetic testing to identify carriers and make informed breeding decisions aimed at reducing the incidence of CMO in future generations.

Scottish Terriers and Cairn Terriers share the same genetic predisposition, likely due to the common ancestry these breeds share with West Highland White Terriers. The clinical presentation in these terrier breeds tends to follow a relatively predictable pattern, with bilateral mandibular involvement as the predominant finding. The onset age, disease duration, and response to treatment are broadly similar across these closely related breeds.

When CMO occurs in non-terrier breeds such as Labrador Retrievers, Great Danes, Doberman Pinschers, and Boxers, the presentation may differ in important ways from the classic terrier pattern. Larger breed dogs with CMO more frequently show involvement of bones beyond the mandible, including the tympanic bullae, occipital bone, and occasionally the long bones of the limbs. The genetic basis in these breeds is less well characterized, and the inheritance pattern may not follow the simple autosomal recessive model seen in terriers.

Bulldog breeds, including English Bulldogs and Boxers, represent another group with documented susceptibility to CMO. In these brachycephalic breeds, the pre-existing skull conformation can complicate both clinical assessment and radiographic interpretation. The shorter, broader skull proportions may mask early mandibular changes or make it more difficult to distinguish CMO-related bone proliferation from the normal exaggerated bony features characteristic of these breeds.

Breed clubs and responsible breeders play a crucial role in managing the prevalence of CMO through informed breeding practices. Affected dogs and known carriers should be removed from breeding programs. Genetic counseling and testing, where available, provide valuable tools for making breeding decisions that reduce the risk of producing affected puppies while maintaining healthy genetic diversity within breed populations.

During the active phase of craniomandibular osteopathy, the impact on a puppy's daily life can be substantial. The intermittent nature of the pain episodes creates an unpredictable pattern of good days and bad days that can be stressful for both the puppy and its owner. On good days, the puppy may appear nearly normal, eating and playing with minimal signs of discomfort. During flare-ups, the same puppy may refuse food, cry when handled around the head, and withdraw from interactions with family members and other pets.

Feeding time often becomes the most challenging aspect of daily management. Owners must experiment with different food textures, temperatures, and presentation methods to find combinations that the puppy will accept during painful episodes. Warming food slightly can make it more aromatic and appealing to a puppy with reduced appetite. Raising food and water bowls to a comfortable height eliminates the need for the puppy to lower its head fully, which can exacerbate jaw pain. Some owners find that syringe-feeding small amounts of calorie-dense liquid diet ensures minimum caloric intake during the worst flare-ups.

Socialization and training, which are critically important during the puppy developmental window, can be disrupted by CMO. Puppies experiencing pain may be less willing to interact with other dogs, explore new environments, or participate in training activities. Owners should take advantage of pain-free intervals to continue socialization efforts, using gentle, positive methods that do not require the puppy to hold objects in its mouth or engage in rough play. Treats used for training may need to be replaced with alternative rewards such as verbal praise or gentle petting during painful episodes.

The emotional toll on owners caring for a puppy with CMO should not be underestimated. Watching a young dog experience recurring episodes of pain can be distressing, and the uncertainty about the eventual outcome adds to the emotional burden. Veterinary professionals can support owners by providing clear education about the expected disease course, realistic prognostic information, and reassurance that the condition will typically resolve with time. Support from breed-specific communities and online forums where other CMO owners share their experiences can also provide valuable emotional support and practical management tips.

Despite the challenges of the active phase, most owners of dogs that have recovered from CMO report that their dogs enjoy completely normal quality of life once the disease has resolved. The period of active disease, while difficult, is temporary, and the investment in careful management during puppyhood is rewarded with a healthy, comfortable adult dog.

Surgical intervention for craniomandibular osteopathy is reserved for a small subset of cases where the disease has produced significant functional impairment that does not resolve with conservative management. The most common surgical indication is temporomandibular joint ankylosis, where excessive bone proliferation has fused or severely restricted the joint, preventing the dog from opening its mouth adequately for eating and basic oral functions even after the active disease phase has ended.

The primary surgical procedure performed for CMO-related jaw restriction is excision arthroplasty of the temporomandibular joint. This procedure involves surgically removing the abnormal proliferative bone and recreating a functional joint space. The goal is to restore sufficient jaw opening to allow the dog to eat comfortably and perform normal oral functions. The surgery requires careful planning, often guided by CT imaging, to identify the precise boundaries of the abnormal bone and its relationship to vital structures including the ear canal, middle ear, and neurovascular bundles in the region.

Partial mandibulectomy or ostectomy may be performed in cases where the abnormal bone mass on the mandible itself is causing significant functional or cosmetic problems. These procedures remove segments of the proliferative bone while preserving as much normal mandibular structure as possible. The mandible has considerable capacity for functional adaptation following partial resection, and most dogs maintain acceptable eating ability even after removal of portions of the mandible.

Post-operative management following surgery for CMO typically includes aggressive pain management, dietary modification during the healing period, and physical therapy to maintain and improve jaw range of motion. Passive jaw-opening exercises may be prescribed to prevent re-ankylosis of the surgical site as scar tissue forms during healing. The success rate for surgical correction of CMO-related jaw restriction is generally good, though some dogs may require revision surgery if proliferative bone continues to form at the surgical site before the dog reaches skeletal maturity.

The decision to pursue surgical intervention should be made collaboratively between the owner and a veterinary surgeon experienced in maxillofacial procedures, ideally a board-certified veterinary surgeon or veterinary dentist. Timing of surgery is an important consideration, as operating during the active phase of CMO carries a higher risk of continued bone proliferation and re-ankylosis compared to surgery performed after the disease has become quiescent.

Prevention of craniomandibular osteopathy centers primarily on responsible breeding practices, as the condition has a well-established genetic basis in the most commonly affected breeds. The identification of the autosomal recessive inheritance pattern in West Highland White Terriers was a landmark finding that provided breeders with the knowledge necessary to make informed mating decisions. By avoiding breeding two carriers of the CMO gene, the production of affected puppies can be entirely prevented within a single generation.

Genetic testing has emerged as the most powerful tool for CMO prevention in predisposed breeds. DNA-based tests can identify affected dogs, carriers, and genetically clear individuals before they are used in breeding programs. The availability of these tests has enabled progressive breeders to systematically reduce the prevalence of CMO while maintaining the genetic diversity necessary for overall breed health. Breed clubs that require or strongly recommend genetic testing as part of their breeding guidelines have seen meaningful reductions in CMO incidence.

For prospective puppy buyers, understanding the risk of CMO in certain breeds is an important component of the purchase decision. Buyers interested in West Highland White Terriers, Scottish Terriers, Cairn Terriers, and other predisposed breeds should inquire about the CMO status of the parents and request documentation of genetic testing. Reputable breeders will be forthcoming about the health testing performed on their breeding dogs and will not breed known carriers to other carriers or affected individuals.

Veterinary professionals play an important role in CMO prevention through client education and breed health counseling. Veterinarians who see clients with terrier breeds should proactively discuss CMO awareness, the availability of genetic testing, and the importance of responsible breeding practices. Early education helps ensure that owners who may consider breeding their dogs in the future understand the genetic implications and take appropriate steps to prevent the birth of affected puppies.

While genetic prevention addresses the root cause of CMO, early detection and prompt treatment remain important for affected individuals. Owners of puppies in predisposed breeds should be educated about the early signs of CMO so that veterinary evaluation can be sought promptly when symptoms first appear. Early diagnosis allows for the timely institution of pain management, which significantly improves the puppy's comfort and quality of life during the active phase of the disease.